Should vascular effects of newer treatments be addressed more completely?

Future Oncol. 2015;11(14):1995-8. doi: 10.2217/fon.15.119.
No abstract available

Keywords: cardio-oncology; cardiotoxicity; dasatinib; imatinib resistance; leukemia; nilotinib; peripheral arterial disease; ponatinib; tyrosine kinase inhibitors; vascular toxicity.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Cardiovascular Diseases / chemically induced*
  • Clinical Trials as Topic
  • Dasatinib / adverse effects
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Humans
  • Imatinib Mesylate / adverse effects
  • Imidazoles / adverse effects
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridazines / adverse effects

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Protein Kinase Inhibitors
  • Pyridazines
  • ponatinib
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Dasatinib